Johnson & Johnson (JNJ)
(Real Time Quote from BATS)
$152.43 USD
-2.21 (-1.43%)
Updated May 20, 2024 11:53 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
JNJ 152.43 -2.21(-1.43%)
Will JNJ be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JNJ
Should You Invest in the Vanguard Health Care ETF (VHT)?
J&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
Other News for JNJ
Inquiry Into Johnson & Johnson's Competitor Dynamics In Pharmaceuticals Industry
Citi Keeps Their Buy Rating on Johnson & Johnson (JNJ)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Johnson & Johnson (JNJ), Eli Lilly & Co (LLY) and Coherus Biosciences (CHRS)
Johnson & Johnson's Dividend Analysis
Wall Street Brunch: Here Comes Nvidia